Daiichi and Ranbaxy - Top 10 deals of 2008

FierceBiotech's top 10 deals of 2008 featuring Daiichi Sankyo's $4.6 billion acquisition of Ranbaxy stock.Who: Daiichi Sankyo
With: Ranbaxy
What: $4.6B stake

Summary: In June Japan's Daiichi Sankyo signed a deal that gave it a leg up in both emerging markets and the generic drug market. The company paid $4.6 billion for a majority stake in India's generics giant Ranbaxy. In addition to the emerging market and generic benefits, Daiichi gained access to Ranbaxy's affordable R&D and manufacturing facilities. Ranbaxy became a subsidiary of Daiichi but Malvinder Singh will remained CEO. The deal was a must for Daiichi, which announced in 2007 that it was aiming for 60 percent over the next three years.

Daiichi and Ranbaxy - Top 10 deals of 2008
Read more on

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Verseau will use the money to start testing its macrophage checkpoint modulators in humans.